News | September 27, 2010

Study Assesses Performance of Heparin Bioactive Surface Covered Stent

September 27, 2010 – A post-market study investigating a new treatment for peripheral artery disease of the superficial femoral artery (SFA) has completed enrollment.

The VIPER study, which is looking at the performance of the Gore Viabahn endoprosthesis with a heparin bioactive surface, enrolled 120 patients.

Forty patients were treated with the endoprosthesis with heparin bioactive surface alone, while the remaining 80 were treated with the endoprosthesis with heparin bioactive surface manufactured with the proximal contoured edge. The contoured edge resulted from a manufacturing process change and may improve flow dynamics at the inlet of the device in conditions of over-sizing.

“Speaking for the Gore VIPER investigators, we are pleased to have completed enrollment and are enthusiastic about determining the results,” said Richard Saxon, M.D., FSIR, director of research for the San Diego Cardiac and Vascular Institute and North County Radiology Medical Group in Oceanside, Calif., and principal investigator for the study. “SFA studies like Gore VIPER help us to determine the best endovascular treatment options for our patients suffering from atherosclerotic occlusive disease. Although many studies fail to include longer lesions, average lesion length treated in the Gore VIPER Study was approximately 18 centimeters, so we are definitely capturing a challenging, real-world experience. Moreover, having both patients with the Gore Viabahn endoprosthesis with heparin bioactive surface alone as well as patients treated with the Gore Viabahn endoprosthesis with heparin bioactive surface manufactured with the proximal contoured edge will hopefully give us some insight into the clinical impact of the contoured edge device.”

Arun Chervu, M.D., of Wellstar Cobb Hospital, Atlanta, and a leading enroller in the VIPER Study, said, “The intent of the study was to initiate a post-market evaluation of Gore Viabahn endoprosthesis with heparin bioactive surface in the treatment of long SFA disease. Our center has used the device to cover lesions up to 40 centimeters in length and we look forward to understanding how the device performs in these challenging clinical circumstances.”

The Gore Viabahn endoprosthesis was originally approved for treating SFA obstructive disease in the United States in 2005. The VIPER study comprises the first multicenter evaluation of the Gore Viabahn endoprosthesis with heparin bioactive surface, which was introduced in the United States in 2007.

For more information: www.goremedical.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init